Yuichi Terawaki

Nishi, 8190006, Japan

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 13 publications

Efficacy and safety of a combination of an insulin secretagogue and a dipeptidyl peptidase-4 inhibitor in Japanese patients with type 2 diabetes mellitus; the repaglinide glucose oscillation study in Fukuoka (REGO-F).

Efficacy and safety of a combination of an insulin secretagogue and a dipeptidyl peptidase-4 inhibitor in Japanese patients with type 2 diabetes mellitus; the repaglinide glucose oscillation study in Fukuoka (REGO-F).

Journal: Diabetology international

Published: November 25, 2019

Combined treatment with DPP-4 inhibitor linagliptin and SGLT2 inhibitor empagliflozin attenuates neointima formation after vascular injury in diabetic mice.

Combined treatment with DPP-4 inhibitor linagliptin and SGLT2 inhibitor empagliflozin attenuates neointima formation after vascular injury in diabetic mice.

Journal: Biochemistry and biophysics reports

Published: November 01, 2018

GLP-1 Receptor Agonist Exendin-4 Attenuates NR4A Orphan Nuclear Receptor NOR1 Expression in Vascular Smooth Muscle Cells.

GLP-1 Receptor Agonist Exendin-4 Attenuates NR4A Orphan Nuclear Receptor NOR1 Expression in Vascular Smooth Muscle Cells.

Journal: Journal of atherosclerosis and thrombosis

Published: July 03, 2018

Efficacy and safety of sodium-glucose cotransporter 2 inhibitor ipragliflozin on glycemic control and cardiovascular parameters in Japanese patients with type 2 diabetes mellitus; Fukuoka Study of Ipragliflozin (FUSION).

Efficacy and safety of sodium-glucose cotransporter 2 inhibitor ipragliflozin on glycemic control and cardiovascular parameters in Japanese patients with type 2 diabetes mellitus; Fukuoka Study of Ipragliflozin (FUSION).

Journal: Endocrine journal

Published: May 29, 2018

Exendin-4, a Glucagonlike Peptide-1 Receptor Agonist, Attenuates Breast Cancer Growth by Inhibiting NF-κB Activation.

Exendin-4, a Glucagonlike Peptide-1 Receptor Agonist, Attenuates Breast Cancer Growth by Inhibiting NF-κB Activation.

Journal: Endocrinology

Published: May 14, 2017

A Probable Case of Burn-out NASH Caused by Panhypopituitarism Secondary to Craniopharyngioma.

A Probable Case of Burn-out NASH Caused by Panhypopituitarism Secondary to Craniopharyngioma.

Journal: Fukuoka igaku zasshi = Hukuoka acta medica

Published: March 01, 2016

Prescription of oral hypoglycemic agents for patients with type 2 diabetes mellitus: A retrospective cohort study using a Japanese hospital database.

Prescription of oral hypoglycemic agents for patients with type 2 diabetes mellitus: A retrospective cohort study using a Japanese hospital database.

Journal: Journal of diabetes investigation

Published: February 24, 2016

Combined Treatment with Exendin-4 and Metformin Attenuates Prostate Cancer Growth.

Combined Treatment with Exendin-4 and Metformin Attenuates Prostate Cancer Growth.

Journal: PloS one

Published: June 28, 2015

Efficacy of dipeptidyl peptidase-4 inhibitor linagliptin in patients with type 2 diabetes undergoing hemodialysis.

Efficacy of dipeptidyl peptidase-4 inhibitor linagliptin in patients with type 2 diabetes undergoing hemodialysis.

Journal: Diabetology & metabolic syndrome

Published: March 05, 2015

Dipeptidyl peptidase-4 inhibitor linagliptin attenuates neointima formation after vascular injury.

Dipeptidyl peptidase-4 inhibitor linagliptin attenuates neointima formation after vascular injury.

Journal: Cardiovascular diabetology

Published: September 03, 2014

Exendin-4, a GLP-1 receptor agonist, attenuates prostate cancer growth.

Exendin-4, a GLP-1 receptor agonist, attenuates prostate cancer growth.

Journal: Diabetes

Published: June 01, 2014

A novel mutation of CLCNKB in a Japanese patient of Gitelman-like phenotype with diuretic insensitivity to thiazide administration.

A novel mutation of CLCNKB in a Japanese patient of Gitelman-like phenotype with diuretic insensitivity to thiazide administration.

Journal: Meta gene

Published: December 24, 2013

Showing 1-12 of 13

Last Updated: 09/26/2026